OBJECTIVE: To determine time to discontinuation in schizophrenic patients who commence RLAI. METHODS: e-STAR (electronic-Schizophrenia Treatment Adherence Registry) is an ongoing international observational study of schizophrenic patients who commence RLAI. Data collected retrospectively (12-months) and prospectively (2-years) included: patient demographics, medications, hospitalisations, Clinical Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF) and adverse events. A priori statistical analyses using Kaplan-Meier curves and proportional hazard regression models included time to discontinuation. RESULTS: Data from 591 patients from 15 hospitals were available for this analysis. The average age was 36.9 [12.5] years (mean [SD]), duration of illness was 11.0 [9.3] years, 71% were male. The baseline CGI-S was 4.5 [1.2] and GAF was 41.8 [14.8]. Ninety-one percent of patients were initiated on 25mg of RLAI. At 12-months 63% of patients were still on RLAI. The reasons for discontinuation were lack of response (14%); loss-to-follow-up (10.5%); other (7.5%); patient or family choice (6%); adverse events (6%); tolerability (2%); and adherence (1.5%). Young age at schizophrenia onset and suicidal behavior at baseline were significant risk factors for time to discontinuation (p<0.04). CONCLUSIONS: The treatment continuation rate with RLAI at 12-months is consistent with the results of Fleischhacker et al (2003), but superior to oral typical and atypical agents (Lieberman et al, 2005). Fleischhacker et al (2003); J Clin Psychiatry 64(10):1250-1257. Lieberman et al (2005); NEJM 353:1209-23.